Juno inks deals with Eli Lil­ly, the Hutch as it looks to leapfrog lead­ers on BC­MA

Juno Ther­a­peu­tics $JUNO is adding a new ap­proach to its BC­MA strat­e­gy for mul­ti­ple myelo­ma af­ter forg­ing an in-li­cens­ing deal through a trio of al­liances that in­cludes Eli Lil­ly.

Lil­ly is hand­ing over rights on LY3039478 to Juno so it can use their gam­ma sec­re­tase in­hibitor in the biotech’s dri­ve to leapfrog the lead­ers in BC­MA — an ac­tive field that has at­tract­ed the at­ten­tion of blue­bird/Cel­gene $BLUE and oth­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER